公司概况 - Rigel Pharmaceuticals 是一家商业阶段的生物技术公司 专注于开发用于治疗血液疾病和某些癌症的口服小分子激酶抑制剂[1] - 公司拥有三款已商业化的产品[1] 作者背景与分析方法 - 作者采用定量与基本面分析 专注于中小市值股票[1] - 投资策略遵循价值投资原则 核心信条之一是不为股票支付过高价格 通过避免可能造成重大损失的定价过高股票来降低风险[1] - 通常持有股票直至其增长前景减弱或市盈率证明出售合理[1]

Steven Jon Kaplan began TrueContrarian.com in August 1996 as a value-investing newsletter which since March 2020 has included two weekly 75-minute Zoom meetings. Steve provides long-term tax and investment planning. He has been trading since 1981 and handles separately managed accounts for qualified clients with a 20% performance fee on net profits and zero management fees. Steve has been quoted frequently by U.S. News and World Report, MarketWatch.com, and Barron's. Steve appeared on Market Watch cable TV ...